[
    [
        {
            "time": "2021-01-27",
            "original_text": "利妥昔首仿将上市，国内生物类似药进度盘点【周观点|长江医药0127】",
            "features": {
                "keywords": [
                    "利妥昔",
                    "首仿",
                    "上市",
                    "生物类似药",
                    "进度",
                    "长江医药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "利妥昔首仿将上市，国内生物类似药进度盘点【周观点|长江医药0127】",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]